Health Condition 1: L818- Other specified disorders of pigmentation
Conditions
Interventions
Intervention1: Platelet rich plasma: PRP PREPARATION:
On the day of procedure,10ml of whole blood will be drawn into tubes containing sodium citrate(anti-coagulant) with a blood to anti-coagulant rati
Sponsors
R Aishwarya Meenaloshini
Eligibility
Inclusion criteria
Inclusion criteria: Patients of both genders above 18 years & below 60 years with infraorbital melanosis. Duration of > 6 months Patients willing to give a written informed consent.
Exclusion criteria
Exclusion criteria: Pregnant and lactating women. Women planning for pregnancy Patients with co-morbidities-DM,SHT,TB,CAD,EPILEPSY,BA Patients on immunosuppressive drugs, anti coagulants Bleeding and coagulation disorders, HIV If patient develops severe side effects like ulceration / intolerant to pain during the treatment If patient wants alternate treatment during the study. If patient wants to discontinue the treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pigmentation will be assessed every 3 weeks using severity index. pigmentation will be scored after comparing it with the surrounding skin objectively using severity score and subjectively by patient satisfaction score. The end point will be the evaluation of clinical response to both the mode of treatment at 24 weeks after treatment initiation. Responses in between the study will be noticed & recorded using Severity Index and patient satisfaction scoreTimepoint: 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Patients will be advised to come for follow up once in 4 weeks Upto 12 weeks to look for late adverse effects & recurrence.Timepoint: 12 weeks | — |
Countries
India
Contacts
Public ContactDr R Aishwarya Meenaloshini
Chengalpattu Medical College
Outcome results
None listed